Record Q2 revenue and strong Sephience sales drove raised 2026 guidance and robust cash position. International launches and early access programs are accelerating growth, while pipeline progress and disciplined capital management support long-term outlook.Based on PTC Therapeutics, Inc. [PTCT] Q2…
Record Q2 revenue and strong Sephience launch drove raised 2026 guidance, with robust U.S. and international uptake and over $2.2B in cash. Strategic refinancing, positive clinical progress, and disciplined expense management position the company for sustained growth.Based on PTC Therapeutics, Inc…
PTC Therapeutics reported second-quarter 2026 results with revenue of $360.5M and net income attributable to common stockholders of $83.5M, driven by strong launch momentum for Sephience and a shift in the company’s product mix toward U.S. sales; diluted EPS was $0.92, versus a loss in the year‑ago…
Q2 2026 saw revenues more than double year-over-year to $360.5 million, driven by Sephience's launch and a $50 million Novartis milestone. Net income reached $83.5 million, reversing a prior-year loss, while strong cash reserves support ongoing R&D and commercialization.Original document: PTC Thera…
Sephience drives strong revenue growth and global expansion, supported by robust clinical data and a broad rare disease pipeline. Votoplam and vatiquinone advance in late-stage trials, while innovative R&D platforms position the company for long-term success.Original document: PTC Therapeutics, Inc…
PTC Therapeutics PTCT has built a diversified global commercial portfolio across multiple rare disease indications, providing a strong foundation for sustainable revenue growth.Sephience: PTCT’s Major Growth DriverPTC’s growth largely depends on Sephience (sepiapterin), its approved therapy for phe…
